Identifying Potential Drug Targets and Biomarkers for MAOB (G4129)

Target Name: MAOB

NCBI ID: G4129

MAOB

Identifying Potential Drug Targets and Biomarkers for MAOB

MAOB, or MAO-A, is a protein that is expressed in platelets, which are the blood cells that play a vital role in blood clotting and circulation. The structure and function of MAOB have been the subject of extensive research in recent years, and it has been identified as a potential drug target and biomarker.

MAOB is a member of the MAO family, which includes several other proteins that play a role in platelet function, including MAO-B, MAO-C, and MAO-D. These proteins are involved in the production of the neurotransmitter serotonin, which plays a role in mood regulation, appetite, and other physiological processes.

MAOB is a 120-kDa protein that is expressed in platelets at a level of around 10% of total platelet count. It is composed of two transmembrane domains and a cytoplasmic tail. The transmembrane domains contain the major functions of the protein, including an extracellular domain that is involved in cell signaling, a transmembrane domain that is involved in the interaction with other proteins, and a cytoplasmic tail that is involved in the localization of the protein to the plasma membrane.

One of the most significant functions of MAOB is its role in platelet function. Platelets are involved in blood clotting and circulation, and they play a vital role in maintaining blood pressure and ensuring that oxygen and nutrients are delivered to the body's cells. MAOB is involved in the production of the hormone thrombin, which is a key factor in blood clotting. Thrombin is produced byMAOB in the liver and then transported to the plasma to help form blood clots.

In addition to its role in platelet function, MAOB has also been identified as a potential drug target. The ability of MAOB to interact with other proteins and the presence of multiple isoleucine repeats in its sequence have made it an attractive target for drug developers. Several companies have filed patents for compounds that target MAOB, and further research is being conducted to determine the efficacy and safety of these compounds.

Another potential use of MAOB is as a biomarker for the diagnosis and monitoring of platelet function disorders. The ability of MAOB to be expressed in platelets makes it a potential indicator of platelet function, and changes in MAOB levels may be an indication of disorders such as microproliferative neoplasm of the bone (MPN) or myelodysplastic syndromes (MDS).

In conclusion, MAOB is a protein that is expressed in platelets and is involved in the production of the hormone thrombin and blood clotting. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to determine the full extent of MAOB's role in platelet function and its potential as a drug target.

Protein Name: Monoamine Oxidase B

Functions: Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed:11134050, PubMed:8665924, PubMed:8316221, PubMed:11049757, PubMed:20493079). Preferentially degrades benzylamine and phenylethylamine (PubMed:11134050, PubMed:8665924, PubMed:8316221, PubMed:11049757, PubMed:20493079)

The "MAOB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAOB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets